Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback